ENTR-601-44
Sponsors
Entrada Therapeutics Inc., Entrada Therapeutics, Inc.
Conditions
Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)
Phase 1
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44)
RecruitingCTIS2024-517584-23-00
Start: 2025-05-16Target: 9Updated: 2026-01-19
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
RecruitingNCT07037862
Start: 2025-06-30End: 2029-03-28Target: 24Updated: 2026-08-13
Phase 2
A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Not yet recruitingCTIS2025-525124-10-00
Target: 11Updated: 2026-06-16
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Not yet recruitingNCT07682129
Start: 2026-08-01End: 2032-03-01Target: 80Updated: 2026-07-02